-
Something wrong with this record ?
Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia
J. Bertrand, H. Dostálová, V. Kryštof, R. Jorda, T. Delgado, A. Castro-Alvarez, J. Mella, D. Cabezas, M. Faúndez, C. Espinosa-Bustos, CO. Salas
Language English Country Switzerland
Document type Journal Article
Grant support
21-06553S
Czech Science Foundation
IGA_PrF_2022_007
Palacký University, Olomouc
ENOCH, No. CZ.02.1.01/0.0/0.0/16_019/0000868
European Regional Development Fund
No21180975.
Conicyt, Chile
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
We report 31 new compounds designed, synthesized and evaluated on Bcr-Abl, BTK and FLT3-ITD as part of our program to develop 2,6,9-trisubstituted purine derivatives as inhibitors of oncogenic kinases. The design was inspired by the chemical structures of well-known kinase inhibitors and our previously developed purine derivatives. The synthesis of these purines was simple and used a microwave reactor for the final step. Kinase assays showed three inhibitors with high selectivity for each protein that were identified: 4f (IC50 = 70 nM for Bcr-Abl), 5j (IC50 = 0.41 μM for BTK) and 5b (IC50 = 0.38 μM for FLT-ITD). The 3D-QSAR analysis and molecular docking studies suggested that two fragments are potent and selective inhibitors of these three kinases: a substitution at the 6-phenylamino ring and the length and volume of the alkyl group at N-9. The N-7 and the N-methyl-piperazine moiety linked to the aminophenyl ring at C-2 are also requirements for obtaining the activity. Furthermore, most of these purine derivatives were shown to have a significant inhibitory effect in vitro on the proliferation of leukaemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos) at low concentrations. Finally, we show that the selected purines (4i, 5b and 5j) inhibit the downstream signalling of the respective kinases in cell models. Thus, this study provides new evidence regarding how certain chemical modifications of purine ring substituents provide novel inhibitors of target kinases as potential anti-leukaemia drugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22016970
- 003
- CZ-PrNML
- 005
- 20220720100044.0
- 007
- ta
- 008
- 220718s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics14061294 $2 doi
- 035 __
- $a (PubMed)35745866
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bertrand, Jeanluc $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile
- 245 10
- $a Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia / $c J. Bertrand, H. Dostálová, V. Kryštof, R. Jorda, T. Delgado, A. Castro-Alvarez, J. Mella, D. Cabezas, M. Faúndez, C. Espinosa-Bustos, CO. Salas
- 520 9_
- $a We report 31 new compounds designed, synthesized and evaluated on Bcr-Abl, BTK and FLT3-ITD as part of our program to develop 2,6,9-trisubstituted purine derivatives as inhibitors of oncogenic kinases. The design was inspired by the chemical structures of well-known kinase inhibitors and our previously developed purine derivatives. The synthesis of these purines was simple and used a microwave reactor for the final step. Kinase assays showed three inhibitors with high selectivity for each protein that were identified: 4f (IC50 = 70 nM for Bcr-Abl), 5j (IC50 = 0.41 μM for BTK) and 5b (IC50 = 0.38 μM for FLT-ITD). The 3D-QSAR analysis and molecular docking studies suggested that two fragments are potent and selective inhibitors of these three kinases: a substitution at the 6-phenylamino ring and the length and volume of the alkyl group at N-9. The N-7 and the N-methyl-piperazine moiety linked to the aminophenyl ring at C-2 are also requirements for obtaining the activity. Furthermore, most of these purine derivatives were shown to have a significant inhibitory effect in vitro on the proliferation of leukaemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos) at low concentrations. Finally, we show that the selected purines (4i, 5b and 5j) inhibit the downstream signalling of the respective kinases in cell models. Thus, this study provides new evidence regarding how certain chemical modifications of purine ring substituents provide novel inhibitors of target kinases as potential anti-leukaemia drugs.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dostálová, Hana $u Department of Experimental Biology, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $1 https://orcid.org/0000000261236450
- 700 1_
- $a Kryštof, Vladimír $u Department of Experimental Biology, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $1 https://orcid.org/0000000158382118 $7 xx0097406
- 700 1_
- $a Jorda, Radek $u Department of Experimental Biology, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000249057126
- 700 1_
- $a Delgado, Thalía $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile
- 700 1_
- $a Castro-Alvarez, Alejandro $u Departamento de Ciencias Preclínicas, Facultad de Medicina, Universidad de La Frontera, Manuel Montt 112, Temuco 4780000, Chile $1 https://orcid.org/0000000183608027
- 700 1_
- $a Mella, Jaime $u Instituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, Avenida Gran Bretaña 1111, Valparaíso 2360102, Chile $u Facultad de Farmacia, Centro de Investigación Farmacopea Chilena, Universidad de Valparaíso, Avenida Gran Bretaña 1093, Valparaíso 2360102, Chile $1 https://orcid.org/0000000224348461
- 700 1_
- $a Cabezas, David $u Instituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, Avenida Gran Bretaña 1111, Valparaíso 2360102, Chile
- 700 1_
- $a Faúndez, Mario $u Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile
- 700 1_
- $a Espinosa-Bustos, Christian $u Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile $1 https://orcid.org/0000000160388439
- 700 1_
- $a Salas, Cristian O $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile $1 https://orcid.org/0000000176202459
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 6 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35745866 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220718 $b ABA008
- 991 __
- $a 20220720100040 $b ABA008
- 999 __
- $a ind $b bmc $g 1816391 $s 1168212
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 6 $e 20220617 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a 21-06553S $p Czech Science Foundation
- GRA __
- $a IGA_PrF_2022_007 $p Palacký University, Olomouc
- GRA __
- $a ENOCH, No. CZ.02.1.01/0.0/0.0/16_019/0000868 $p European Regional Development Fund
- GRA __
- $a No21180975. $p Conicyt, Chile
- LZP __
- $a Pubmed-20220718